Multi-neo-epitope Vaccine OSE 2101 clinical trials
Also written OSE2101 and EP2101.
How each study uses Multi-neo-epitope Vaccine OSE 2101 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Multi-neo-epitope Vaccine OSE 2101 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2003 | 2 |
| 2004 | 1 |
| 2016 | 1 |
| 2021 | 3 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 4
Epimmune (3) · Fondazione Ricerca Traslazionale (2) · OSE Immunotherapeutics (2) · GERCOR - Multidisciplinary Oncology Cooperative Group (1) · ARCAGY/ GINECO GROUP (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test Multi-neo-epitope Vaccine OSE 2101.
- Sep 2027Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)Phase 2 · Fondazione Ricerca Traslazionale
- Oct 2027A Randomized Phase II Trial of Cemiplimab Plus OSE2101 ( TEDOPI®) as Maintenance Therapy in ctDNA Positive NSCL. The Cemited Study.Phase 2 · Fondazione Ricerca Traslazionale
Studies
Open first, then newest update. How each study uses Multi-neo-epitope Vaccine OSE 2101 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint InhibitorRecruitingPhase 3OSE ImmunotherapeuticsNCT06472245Written as OSE2101How we know
- A Randomized Phase II Trial of Cemiplimab Plus OSE2101 ( TEDOPI®) as Maintenance Therapy in ctDNA Positive NSCL. The Cemited Study.RecruitingPhase 2Fondazione Ricerca TraslazionaleNCT07264673Written as TedopiHow we know
- OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OCCompletedPhase 2ARCAGY/ GINECO GROUPNCT04713514Written as OSE2101How we know
- Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)Active, not recruitingPhase 2Fondazione Ricerca TraslazionaleNCT04884282Written as TedopiHow we know
- OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDACActive, not recruitingPhase 2GERCOR - Multidisciplinary Oncology Cooperative GroupNCT03806309Written as OSE2101How we know
- OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor FailureTerminatedPhase 3OSE ImmunotherapeuticsNCT02654587Written as OSE2101How we know
- Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung CancerStatus unknownPhase 2EpimmuneNCT00104780Written as EP-2101How we know
- An Open Label Study of a Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung CancerCompletedPhase 1EpimmuneNCT00054899Written as EP2101How we know
- An Open Label Study of a Peptide Vaccine in Patients With Stage III Colon CancerCompletedPhase 1EpimmuneNCT00054912Written as EP2101How we know